Genta - Waiting For Genasense To Make Sense Trading Markets (press release), CA - Chronic lymphocytic leukemia is a type of blood cancer, affecting white blood cells called lymphocytes, which help the body fight infection. The New Drug...OTC:GNTA
Potential New Drug Target For Chronic Leukemia Science Daily (press release) - Nov 24, 2008 "PDE7B is thus a new drug target for CLL," he said. "We have preliminary data from patient samples studied in the laboratory showing that we can increase ...
For departing Sen. Migden, 'a bittersweet time' San Francisco Chronicle, USA - After the accident in May 2007, Migden said she had been diagnosed with leukemia for 10 years. While the cancer is in remission, she said she had been ...
World AIDS Day - 20 Years And 33 Million Sufferers InjuryBoard.com, FL - The man had the transplant to wipe out leukemia. Stem cell transplants require wiping out a patient?s immune system with radiation and drugs, ...
Salmonella Is Tested To Fight Cancer Cells Wall Street Journal - Gleevec was approved by the US Food and Drug Administration in 2003 specifically to treat chronic myelogenous leukemia, a disease that can lead to anemia, ...
A Drug Stock With a Promising Pipeline Barron's - Aug 5, 2008 In an environment that has thwarted many drug makers' attempts to introduce new products, Cephalon has launched two new drugs that could help reverse last ...CEPH
OncoVista is testing new drug in fight against leukemia Bizjournals.com, NC - Jul 22, 2008 ?We believe cordycepin will prove to be an effective and well-tolerated treatment option for many leukemia patients who do not respond to other therapies. ...
Genmab, GSK Report Mid-Term Findings for Leukemia Drug FDA news (subscription), VA - Aug 5, 2008 Based on promising interim results from a Phase III study in patients with refractory chronic lymphocytic leukemia, Genmab and GlaxoSmithKline (GSK) expect ...CPH:GEN
Craig W. Philips Takes Helm at CTI FOXBusiness - Aug 5, 2008 "With the opportunity to bring two new cancer drugs to market and expand the label of another in the near term, CTI could transform itself into a successful ...CTIC - OTC:CMTX
This little drug went to market Sydney Morning Herald, Australia - Jul 30, 2008 Two years ago, six healthy young men in London were paid $5000 each to trial a new drug targeting auto-immune and inflammatory diseases. ...
Source: Google News
Chromatin remodeling and leukemia: new therapeutic paradigms. - RL Redner, J Wang, JM Liu - Blood, 1999 - ncbi.nlm.nih.gov ... here to read Chromatin remodeling and leukemia: new therapeutic paradigms. ... Acetylation;
Antineoplastic Agents/therapeutic use; Cell Differentiation/drug effects; ...
Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia - PF Bross, J Beitz, G Chen, XH Chen, E Duffy, L … - Clinical Cancer Research, 2001 - AACR ... present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). ...
groups was a central issue in the review of this newdrug application (NDA ...
Novel mechanisms of drug resistance in leukemia - DD Ross - nature.com ... expression of BCRP mRNA is observed in approximately 30% of AML cases, suggesting
a potential role for this new transporter in drug resistance in leukemia. ...
People with two types of leukemia now have a new treatment option when other therapies fail. The US Food and Drug Administration has approved Sprycel (dasatinib) for people with chronic myeloid leukemia (CML) who are resistant to Gleevec (imatinib) or can't tolerate the drug, and for people with Philadelphia chromosome-positive acute lymphocytic leukemia (ALL) who are no longer being helped by their treatment.
Sprycel is made by Bristol-Myers-Squibb. The company said it should be available throughout the US within a few days. It comes as a tablet patients take twice a day.
CML is a fairly uncommon disease in the US. It is expected to strike about 4,500 people in 2006 and kill about 600. The pill Gleevec is very effective for CML and has helped many people live longer with this disease. However, some people cannot tolerate the drug, and others eventually develop resistance to it.
ALL is also uncommon. About 3,930 new cases and 1,490 deaths are expected in the US in 2006. Philadelphia chromosome-positive ALL is a more serious form of the disease, and people who have it typically develop treatment resistance sooner.
Now, people in these situations have another treatment they can try. Sprycel is a targeted therapy that works by blocking the activity of proteins that cause leukemia cells to grow.
Survival Benefit Unknown
In clinical trials of more than 400 people who could no longer take Gleevec, about 45% of people with early stages of CML had a response to the drug, meaning they had either no detectable leukemia cells in their blood after treatment, or a significant reduction in the number of leukemia cells. For people with more advanced CML and with ALL, the response rates ranged from 31% to 59%, the FDA said.
However, it is not yet known whether Sprycel helps patients live longer. Studies are under way to find out if it does.
Side effects from Sprycel may include fluid retention, bleeding, diarrhea, skin rashes, infections, headaches, fatigue, and nausea. It can also cause anemia, low white blood cell counts, and low platelet counts. Pregnant women should not take the drug because it can harm the fetus, and patients who are sexually active should use contraception while on Sprycel, Bristol-Myers-Squibb said.
